At least the damage at Theranos was confined to professional investors, Reuters writes in this opinion piece. Elizabeth Holmes’ blood-testing outfit touted novel technology and big future sales before its collapse. Holmes, whose trial starts today, blurred the lines between marketing and fraud, and Theranos’ multibillion-dollar private-market valuation dwindled to nothing. Fast forward and Trevor Milton, founder of electric-truck firm Nikola is facing similar charges. Nikola, though, has publicly traded shares. Read more.
Today’s Theranos Would Have Gone Public via a SPAC: Commentary
